The sale of 1,000 Artemisinin-based combination therapies (ACT) in the form of a pre-packed treatment (PPT) in Nigeria averts 68 DALY, or 68 years of healthy life that would have been lost without PSI’s intervention. The difference in calculating DALY for treatment and prevention products can be expressed in terms of targeting. Treatment products are almost perfectly targeted because the beneficiary is someone who is already suffering from the condition (save for misdiagnosis and wastage). For example, a bed net may be used to protect children who would not have become infected with malaria. How much of a prevention product is wasted depends on the level of risk in the population and the effectiveness of the targeting efforts. Since treatment products are mostly consumed by people who are already sick this means less wastage and therefore higher unit effectiveness.